GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » Degree of Financial Leverage

Conduit Pharmaceuticals (Conduit Pharmaceuticals) Degree of Financial Leverage : 0.43 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Conduit Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 0.43. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Conduit Pharmaceuticals's Degree of Financial Leverage or its related term are showing as below:

CDT's Degree of Financial Leverage is ranked better than
73.97% of 1498 companies
in the Biotechnology industry
Industry Median: 0.97 vs CDT: 0.43

Conduit Pharmaceuticals Degree of Financial Leverage Historical Data

The historical data trend for Conduit Pharmaceuticals's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Degree of Financial Leverage Chart

Conduit Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23
Degree of Financial Leverage
- 0.63 0.50

Conduit Pharmaceuticals Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial 0.63 - - 0.50 0.43

Competitive Comparison of Conduit Pharmaceuticals's Degree of Financial Leverage

For the Biotechnology subindustry, Conduit Pharmaceuticals's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conduit Pharmaceuticals's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's Degree of Financial Leverage falls into.



Conduit Pharmaceuticals Degree of Financial Leverage Calculation

Conduit Pharmaceuticals's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.04 (Mar. 2024) / -0.078 (Mar. 2023) - 1 )/( 0.709 (Mar. 2024) / -5.699 (Mar. 2023) - 1 )
=-0.4872/-1.1244
=0.43***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Conduit Pharmaceuticals  (NAS:CDT) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Conduit Pharmaceuticals Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Conduit Pharmaceuticals (Conduit Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Murphy Canyon Road, Suite 300, San Diega, CA, USA, 92123
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Executives
Intelmed Llc other: See Responses 11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay director, officer: Chief Executive Officer 32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Andrew Regan director, 10 percent owner LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc. 10 percent owner, other: See Responses 100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd. 10 percent owner, other: See Responses WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh director 38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc 10 percent owner 230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg director 2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc 10 percent owner 4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley director 4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv officer: Chief Accounting Officer 2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron director, officer: CEO, President, and Chairman 16433 BRONCO LANE, POWAY CA 92064